



Structured Administration and Supply Arrangement (SASA)

TITLE: **Treatment of Sexually Transmitted Infection by Aboriginal Health Practitioners**

1. Authority:

Issued by the Chief Executive Officer of Health under Part 6 of the Medicines and Poisons Regulations 2016.

2. Scope:

This authorises Aboriginal Health Practitioners working in a public health program to administer and supply antibiotics and related treatments, for treatment of a Sexually Transmitted Infection (STI).

3. Criteria:

This SASA authorises the actions specified in the table below.

Practitioner:	Registered Aboriginal Health Practitioners who have completed approved training in accordance with Appendix 1
Practice setting:	Public health STI programs operated or managed by a Health Service Provider of WA Health, or contracted entity. All regions of WA.
Approved activity:	Administration
Approved medicines:	Medicines as listed in Appendix 2: <ul style="list-style-type: none">• azithromycin; or• azithromycin, amoxicillin, probenecid; or• azithromycin, ceftriaxone and lignocaine.
Medical conditions:	Chlamydia and / or gonorrhoea in adults and mature minors (aged 14 years or older): <ul style="list-style-type: none">• cases confirmed by laboratory or point of care testing;• empirical treatment of symptomatic cases; or• asymptomatic sexual contacts of confirmed cases.

4. Conditions:

The administration or supply of approved medicines under this SASA is subject to the conditions that:

- a. Patient selection, administration and follow up care is in accordance with the *Guidelines for managing sexually transmitted infections and blood-borne viruses* ("The Silver Book") and Appendix 2;
- b. Supply is not repeated for the same instance of the condition, without the direction of a medical practitioner, credentialed for a public health STI program by a Health Service Provider of WA Health, or contracted entity;
- c. The medicines are procured by an authorised person or an appropriate Medicines and Poisons Permit holder;
- d. Procurement and storage of the approved medicines is in accordance with Part 9 of the Medicines and Poisons Regulations 2016; and
- e. Record keeping of administration is in accordance with Part 12 of the Medicines and Poisons Regulations 2016.
- f. Laboratory confirmed diagnosis of chlamydia and/or gonorrhoea must be notified to the Director, Communicable Disease Control Directorate, Department of Health, by post, telephone or facsimile, preferably within 24 hours.
- g. Notification must comply with the Procedure for Notification of Communicable Diseases (Excluding HIV/AIDS) and be in an approved notification format.

5. References:

- a. *Guidelines for managing sexually transmitted infections and blood-borne viruses*. Available at: <http://ww2.health.wa.gov.au/Silver-book>
- b. Communicable Disease Control Directorate. *Notification of Communicable Diseases*. Available at: <http://ww2.health.wa.gov.au/Silver-book/STI-or-HIV-notification>

6. Issued by:

Name:	Dr Andrew Robertson
Position:	A/Chief Health Officer
Date:	10 September 2018

Enquiries to:	Medicines and Poisons Regulation Branch	Number:	014/1-2018
	poisons.regulation@health.wa.gov.au	Date:	10/09/2018

APPENDIX 1

Approved Training

All Aboriginal Health Practitioners administering a medicine in accordance with this SASA must have successfully completed a course of training approved by the Chief Executive Officer of the Department of Health or an equivalent course provided by a Registered Training Organisation (RTO) or a university, and must maintain their competency through updates every two years.

Approved courses must require participants to demonstrate satisfactory knowledge, understanding and minimum competencies in the following areas:

- a. Sexual health history taking;
- b. Sexual health and STI clinical assessment;
- c. Pathology testing, including request and collecting samples;
- d. Contraindications and adverse effects of azithromycin, amoxicillin, probenecid, ceftriaxone and lignocaine;
- e. STI health promotion and education;
- f. STI contact tracing;
- g. Communicable disease notification and referral; and
- h. Reporting of suspected child sexual abuse.

APPENDIX 2

Approved Settings, Medicines and Conditions

Approved treatments

Treatment	Agent		Dosage	Route	
Azithromycin =	Azithromycin		1 gram	oral	single dose
“ZAP” pack =	Azithromycin	with	1 gram	oral	single dose
	Amoxicillin	and	3 gram		
	Probenecid		1 gram		
“LAC” pack =	Azithromycin	with	1 gram	oral	single dose
	Ceftriaxone with lignocaine 1%		500 mg in 2 ml	deep intramuscular injection	

Treatment recommendations

Client		STI acquired in	Treatment
<ul style="list-style-type: none"> Empirical treatment of symptomatic clients Laboratory or Point of Care testing confirmed cases 	Uncomplicated gonorrhoea + / - chlamydia	Goldfields, Kimberley, Pilbara	ZAP
		Rest of WA and elsewhere	LAC
<ul style="list-style-type: none"> Sexual partners of confirmed cases 	Uncomplicated chlamydia	Goldfields, Kimberley, Pilbara	Azithromycin
		Rest of WA and elsewhere	Azithromycin

Treatment notes

- Consent to treatment should be obtained, as required, in accordance with local organisational policy
- Clients should be advised of expected adverse events and provided with a treatment fact sheet - <http://ww2.health.wa.gov.au/Patient-fact-sheets>
- For clients with a history of allergy to any component of treatment, or other contraindication - do not administer treatment - seek further advice from a medical practitioner
- For management of any reported adverse events - seek further advice from a medical practitioner
- Clients should be directly observed while taking oral doses